CASI Pharmaceuticals disclosed that its Phase 1 open‑label study of the anti‑CD38 antibody CID‑103 in adult patients with immune thrombocytopenia (ITP) achieved a primary endpoint in 12 of 15 evaluable subjects, a 80% success rate, and a 66% complete response rate, with platelet counts improving as early as one week after treatment initiation.
The safety profile remained manageable; only two Grade 3 adverse events were reported, and no serious infections or thrombotic events were observed, reinforcing the consistency of the safety signals first presented at the 67th American Society of Hematology meeting on December 7 2025.
In addition to the clinical update, CASI’s board received a preliminary, non‑binding take‑private proposal from Dr. Wei‑Wu He, who offered $1.15 per share—approximately a 30% premium to the 30‑day average closing price. The proposal is still under review, and the board has not yet made a decision.
The announcement triggered a positive market reaction; CASI shares rose 3.29% in after‑hours trading, outperforming peers that declined, as investors weighed the stronger efficacy data and the attractive acquisition offer.
The new data strengthen CASI’s pipeline focus on immune‑mediated disorders and organ transplant rejection, while the acquisition proposal could accelerate the company’s exit strategy. The company also recently secured a Nasdaq listing extension to meet the February 17, 2026 compliance deadline, underscoring its ongoing efforts to maintain regulatory standing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.